Update on oncogenesis and therapy for Kaposi sarcoma

Purpose of review This review is an update of the recent findings on pathophysiology of Kaposi sarcoma, the role of HHV-8 in Kaposi sarcoma pathogenesis and to summarize the recent advances in the treatment of Kaposi sarcoma and the role of immunity to control the disease. Recent findings The causal agent of Kaposi sarcoma is HHV-8 and the mechanism by which HHV-8 drives the tumor development is unique. HHV-8 is not a classic oncogenic virus and the disease is an opportunistic tumor responding to immune restoration when it is possible. Summary Five epidemiologic types of Kaposi are recognized and HHV-8 is associated to all epidemiologic forms of Kaposi. HHV-8 is a virus favoring both angiogenesis and cellular proliferation, which are the two main histological features of Kaposi sarcoma. Although in many cases, treatment of Kaposi sarcoma is not necessary, specific chemotherapy, immunomodulation and immune stimulation are the tools for treating Kaposi sarcoma. Monochemotherapy has been shown to be as efficient as polychemotherapy and less toxic. Immune checkpoint inhibitors gave some promising results, which should be confirmed by prospective studies.
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: MELANOMA AND OTHER SKIN NEOPLASMS: Edited by CĂ©leste Lebbe Source Type: research

Related Links:

Conclusions: Since its introduction, PERCIST 1.0 has been increasingly used in many clinical trials and prospective studies, with variable reporting of metabolic response and survival data. In general, it appears PERCIST response is associated with longer PFS and survival though the heterogeneity of disease, scan timing and therapies make data pooling difficult. Prospective inclusion of the PERCIST 1.0 criteria in clinical trials using FDG, with baseline, early monitoring, and end of therapy scans could inform cancer clinical trials. Support: 5U01CA140204-04 Reference: 1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: NET and Others II Source Type: research
Conclusion: These preliminary data suggest that measuring skin flap tissue oxygenation intraoperatively, with NIR spectroscopy, can differentiate objective variations in perfusion that are associated with clinical outcomes.
Source: Plastic and Reconstructive Surgery – Global Open - Category: Cosmetic Surgery Tags: Original Article Source Type: research
ConclusionsSurvival of sarcoma-SMN patients is worse than sarcoma-FMN patients. Although survival and tumor characteristics appear similar for breast-SMN and breast-FMN patients, treatment differs; breast-SMN patients less often receive breast-conserving therapy. Larger studies are necessary to substantiate these exploratory findings.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
Conclusions: The %changes of SUVmax both on PET2 and PET3 could predict the outcome of patients with osteosarcoma of the extremities. The %changes of SUVmax on PET3 better predicted the outcome than histologic response.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Sarcoma/ Melanoma Source Type: research
Conclusions: In this retrospective analysis of patients with advanced melanoma treated with the PD-1 antibody pembrolizumab, tumor burden on FDG PET was highly significantly correlated with OS. Tumor burden on PET may allow investigators to better stratify patients in clinical trials of new immunotherapeutic agents and help clinicians with treatment decisions for individual patients.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Sarcoma/ Melanoma Source Type: research
Conclusions The recent, first randomized clinical trial demonstrated overall and progression free survival benefits after SBRT to oligometastatic disease which supports prior retrospective case series (6). The spine is a common site of metastatic bone disease, and as high quality data continue to mature, along with completion of additional randomized clinical trials, it is expected that utility of SBRT to the spine will increase in the future. Spine SBRT is unique due to the requirement of sharp dose falloff to prevent serious neurologic morbidity. With recent advances in radiotherapy planning, robotic patient positionin...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Fatima Bilal1,2,3,4, Anne Montfort1,2,4, Julia Gilhodes5, Virginie Garcia1,2, Joëlle Riond1,2, Stéphane Carpentier1,2,4, Thomas Filleron5, Céline Colacios1,2,4, Thierry Levade1,2,4,6, Ahmad Daher3, Nicolas Meyer1,4,5, Nathalie Andrieu-Abadie1,2 and Bruno Ségui1,2,4* 1INSERM UMR 1037, CRCT, Toulouse, France 2Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France 3Ecole Doctorale de Sciences et Technologies, Université Libanaise, Beirut, Lebanon 4Université Toulouse III – Paul Sabatier, Toulouse, France 5Institut Universitaire du Cancer, Toulouse, France 6L...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Michal Yalon1†, Amos Toren1,2†, Dina Jabarin2, Edna Fadida3, Shlomi Constantini3 and Ruty Mehrian-Shai1* 1Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel 2The Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel 3Department of Pediatric Neurosurgery, Dana Children's Hospital, Tel-Aviv-Sourasky Medical Center, Tel Aviv, Israel Pediatric brain tumors are the most common solid tumor type and the leading cause of cancer-related death in children. The immune system plays an important r...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion Several TISC-based immunotherapeutic approaches are under development in various stages of preclinical studies. As outlined in this review article, a careful and more exhaustive genetic and metabolic understanding of TISC-associated phenotypes is critical to develop novel TISC based immunotherapies. Various components within the tumor microenvironment such as tumor cells, infiltrating immune cells, and supporting stromal cells impact the TISC metabolism. This unique metabolic profile leads to upregulation of certain enzymes and proteins such as ALDH1, CEP55, IDO COA1 etc., which can be utilized for development ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chemotherapy | Epidemiology | Melanoma | Sarcomas | Skin | Skin Cancer | Study | Toxicology